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Colorectal cancer (CRC) screening with colonoscopy is commonly used in patients who are candidates for liver 
transplantation. We initiated this study to define the risk-benefit ratio of performing screening colonoscopy in this 
population. A retrospective observational study of all consecutive patients undergoing colonoscopy during pre–liver 
transplantation screening between 2004 and 2017 was conducted. Endoscopic and pathological findings and clinical 
events potentially related to the colonoscopy in the 30 days after the procedure were registered and compared with 
a 30-day inpatient control time frame. A total of 858 colonoscopies were performed in 808 patients (65% male; me-
dian age, 55 years [interquartile range (IQR), 47-62]; median model for end-stage liver disease (MELD) score, 15 
[IQR, 11-18]). CRC was found in 2 patients (0.2%), and advanced adenomas were found in 44 patients (5.4%). The 
only independent risk factor for an advanced neoplasm was age (odds ratio, 1.072 per year; 95% confidence interval, 
1.031-1.115; P < 0.001). During the 30-day postprocedure period, 178 clinical events occurred in 128 patients com-
pared with 101 clinical events in 72 patients in the control time frames (P < 0.001). After colonoscopy, there was a 
significantly increased risk for renal failure (P = 0.001) and gastrointestinal (GI) bleeding (P = 0.023). Presence of 
ascites and MELD score were identified as independent risk factors for acute renal failure and GI bleeding. During 
the study observation period, 53.5% of the screened population actually underwent liver transplantation. Conclusion: 
CRC screening in pre–liver transplantation patients is associated with a relatively low prevalence of CRC and an 
increased risk of postcolonoscopy complications such as acute renal failure and GI bleeding, especially in patients 
with advanced liver disease. Because the risk-benefit ratio of standard performance of a screening colonoscopy in 
this population appears questionable, alternative screening strategies should be considered. (Hepatology 
2019;69:2598-2607).
Colonoscopy is commonly performed as part of the standard screening for neoplastic lesions in patients who are candidates for liver trans-
plantation, although international guidelines do not 
clearly state in which patients it should be mandato-
rily performed or might be omitted.(1-3)
The prevalence of colorectal cancer (CRC) in liver 
transplantation candidates has not been well defined. 
Abbreviations: CI, confidence interval; CRC, colorectal cancer; FIT, fecal immunochemical test; GI, gastrointestinal; HCC, hepatocellular 
carcinoma; HE, hepatic encephalopathy; IBD, inflammatory bowel disease; INR, international normalized ratio; IQR, interquartile range; 
MELD, model for end-stage liver disease; OR, odds ratio; PSC, primary sclerosing cholangitis; SBP, spontaneous bacterial peritonitis; SD, standard 
deviation; SSA/P, sessile serrated adenoma/polyp; TSA, traditional serrated adenoma.
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Several studies have reported that the prevalence of 
premalignant colon lesions (i.e., advanced adeno-
mas) in this patient population varies from 5.8% to 
13.9%.(4-8) Removal of these precursor lesions is rec-
ommended, considering the potentially accelerated 
rate of progression to CRC during long-term immu-
nosuppressive therapy after transplantation.(9)
In addition, few quantitative data are available per-
taining to the safety of colonoscopy in this popula-
tion. Several case series have suggested that patients 
with end-stage liver disease undergoing colonoscopy 
are at increased risk for hemorrhage and perforation 
after polypectomy.(10,11) Other reported complications 
include bacteremia, peritonitis, and renal failure.(12-19)
The aim of the present study was to assess the yield 
and safety of screening colonoscopy in a large consec-
utive cohort of patients who underwent evaluation for 
liver transplantation by investigating the prevalence 
and predictive factors for CRC and advanced adeno-
mas and the incidence and predisposing factors for 
postprocedural complications.
Patients and Methods
StUDy DeSIgN aND patIeNtS
All consecutive patients undergoing colonos-
copy during pre–liver transplantation screening from 
January 1, 2004, to May 1, 2017, in the Erasmus 
Medical Center, Rotterdam, the Netherlands, were 
retrospectively included. The study protocol conforms 
to the ethical guidelines of the 1975 Declaration of 
Helsinki as reflected in approval by the institution’s 
human research committee on January 23, 2017. 
Written informed consent was not necessary, consid-
ering the nature of the study.
ColoNoSCopy pRoCeDURe
Bowel preparation was achieved using polyeth-
ylene electrolyte glycol (PEG) solutions. Sedation, 
using midazolam and/or fentanyl, was performed at 
the discretion of the patients’ preference and physi-
cians’ judgement. Endoscopic reports were retrieved 
from the automated EndoALPHA reporting system 
(ENDOBASE; Olympus Winter & Ibe, Hamburg, 
Germany). Specimens of resected colon tissue were 
processed and reviewed by specialized gastrointes-
tinal (GI) pathologists using standard histologic 
methods.
Data ColleCtIoN
Clinical patient characteristics at the time of 
colonoscopy, including sex, age, cause and sever-
ity of liver disease, presence of hepatocellular car-
cinoma (HCC), presentence of ascites (graded as 
none, diuretic-responsive, and refractory), presence 
of hepatic encephalopathy (HE) (graded according 
to the West-Haven criteria), and laboratory values 
(creatinine, albumin, bilirubin, and international nor-
malized ratio [INR]), were collected from electronic 
patient records. Data of the colonoscopy procedure, 
including use of premedication, adequacy of bowel 
preparation, cecal intubation rate, tumor size, mor-
phologic and histopathologic characteristics, polyps, 
and other endoscopic findings (e.g., inflamma-
tory bowel disease [IBD], rectal varices, and portal 
enteropathy), were recorded. In the context of this 
study, patients were followed until 1 year after liver 
transplantation, until the date of death when not 
undergoing transplant, or until the end of the study 
observation period (August 1, 2018) when they were 
still on the waiting list.
aRtICle INFoRMatIoN:
From the 1 Department of Gastroenterology and Hepatology,  Erasmus Medical Center University Hospital, Rotterdam, 
the Netherlands; 2 Department of Biostatistics,  Erasmus Medical Center University Hospital, Rotterdam, the Netherlands.
aDDReSS CoRReSpoNDeNCe aND RepRINt ReQUeStS to: 
Rosalie C. Oey, M.D. 
Department of Gastroenterology and Hepatology
Erasmus MC University Hospital 
Room Na-606 
P.O. Box 2040 
3000 CA Rotterdam, the Netherlands 
E-mail: r.oey@erasmusmc.nl 
Tel.: +316-12894554 
Hepatology, June 2019OEY, VAN TILBURG ET AL.
2600
CoMplICatIoNS
All clinical events potentially related to the colo-
noscopy were registered in the 30-day period after 
the procedure. To assess colonoscopy-associated risk 
in comparison with the general risk in this partic-
ular population, relevant clinical events were also 
registered in the 30-day period preceding the pro-
cedure when this was performed in even years (e.g., 
2004, 2006, and so on) and between day 31 and day 
60 after the procedure when this was performed in 
uneven years (Fig. 1). Patients who received a liver 
transplantation or who died during the control time 
frame were not taken into account with respect 
to the assessment of complications. The following 
events were considered to be potentially related to 
colonoscopy: postpolypectomy hemorrhage, colon 
perforation, acute renal failure, GI bleeding, new 
onset or worsening of ascites and HE, bacterial 
infections (including bacteremia, fever of unknown 
origin, spontaneous bacterial peritonitis [SBP], and 
respiratory, urogenital, and other infections), car-
diopulmonary events (including new-onset arrhyth-
mias, myocardial infarction, congestive heart failure, 
aspiration pneumonia, and respiratory insufficiency), 
and significant rise in serum bilirubin.
DeFINItIoNS
Liver disease severity scores were calculated, and 
patients were classified according to Child-Pugh 
class.(20) The model for end-stage liver disease (MELD) 
score was calculated with the following formula: 
0.957 × log(creatinine in milligrams per deciliter) + 
0.378 × log(bilirubin in milligrams per deciliter) + 
1.120 × log(INR) + 0.643.(21,22) The adequacy of bowel 
preparation was classified as inadequate, poor, fair, good, 
or excellent using the Aronchick bowel preparation 
scale.(23,24) Cecal intubation was defined as complete 
visualization and intubation of the cecum, confirmed 
by the visual landmarks of the ileocecal valve and trira-
diate cecal fold.(25) Patients with an inadequate or poor 
bowel preparation were excluded from cecal intubation 
rate calculations. Colon tissue specimens were classified 
as normal colon tissue, hyperplastic polyps, inflamma-
tory polyps, nonadvanced adenomas, advanced adeno-
mas, or CRC.(26) Nonadvanced adenoma was defined 
as all tubular adenoma and serrated nonadvanced ade-
noma.(26) Sessile serrated adenoma/polyp (SSA/P) 
was defined as predominantly architectural distortion 
with irregular dilated crypts that often have an L or 
T shape.(27) Traditional serrated adenoma (TSA) was 
defined as protuberant or pedunculated grown pattern 
with distorted villiform configurations, with colum-
nar cells having abundant eosinophilic cytoplasm or 
centrally located elongated nuclei.(27) Advanced ade-
nomas were defined as adenomas ≥10 mm, adenomas 
with high-grade dysplasia, or adenomas with a villous 
component of at least 25%.(26,28) Cancers were staged 
according to the TNM staging system, described in 
the seventh edition of the American Joint Committee 
on Cancer staging manual.(29) Advanced neoplasia was 
defined as advanced adenoma and/or CRC.
Acute renal failure was defined as a serum creatinine 
increase by 50% or more within 7 days or an increase 
FIg. 1. Schematic view of the chosen control time frames in this study.
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of 0.3 mg/dL (26.5 μmol/L) within 2 days.(30,31) GI 
bleeding was defined as all forms of variceal bleed-
ing in the upper or lower GI tract (thus excluding 
bleeding form a polypectomy site).(32) New-onset or 
worsening HE was defined as newly diagnosed HE 
or an increase of neurocognitive changes according 
to the West-Haven clinical criteria.(33,34) New-onset 
ascites or worsening ascites were defined as a sudden 
increase of ascites and confirmation by ultrasound 
or fluid drainage by paracentesis. Bacterial infections 
were classified using Centers for Disease Control and 
Prevention criteria.(35,36) Fever of unknown origin 
was defined as a prolonged febrile illness that persists 
without diagnosis after careful initial assessment.(37) 
SBP was defined as a polymorphonuclear cell count in 
ascites ≥250/μL without a surgically treatable abdom-
inal source of infection.(38) A bilirubin increase was 
defined as an increase of at least 5 mg/dL (85 μmol/L) 
within 2 days.
StatIStICal aNalySIS
Continuous variables were reported as the mean 
with standard deviation (SD) after visual confirmation 
of approximate normality and were compared using 
the Student t test. Continuous variables with a non-
normal distribution were reported as the median with 
interquartile range (IQR) expressed as the twenty- 
fifth to the seventy-fifth percentile. Categorical vari-
ables were reported as count with proportion and 
compared using the chi-square test. A two-sided 
P value < 0.05 was considered significant.
Multivariable logistic regression, carried out to 
identify risk factors for cecal intubation failure, 
included the following candidate predictor vari-
ables: sex, age, MELD score, ascites, HE, and seda-
tion medication during colonoscopy. Multivariable 
logistic regression, carried out to identify risk factors 
for an advanced neoplasm, included the following 
candidate predictor variables: sex, age, liver disease 
cause, HCC, MELD score, and CRC screening 
(i.e., colonoscopy, fecal occult blood test [FOBT]/
fecal immunochemical test [FIT], computed tomog-
raphy [CT] colonography, or barium enema exam-
ination) in the prior 5 years. Multivariable analyses 
for the logistic regression models were employed 
using the backward stepwise selection method with 
removal testing based on the significance of the like-
lihood-ratio statistic.
Kaplan-Meier analysis was used to estimate 1-year 
and 2-year survival rates after liver transplantation.
All statistical analyses were performed using IBM 
SPSS Statistics for Windows, version 24.0.0.1 (IBM 
Corp., Armonk, NY).
Results
patIeNt CHaRaCteRIStICS
From January 1, 2004, to May 1, 2017, 1,145 patients 
underwent pre–liver transplantation screening in the 
Erasmus MC, Rotterdam, the Netherlands. A total of 
337 patients were not included in the study, mainly 
because colonoscopy was performed in a referring hospi-
tal (n = 90), patients were listed with highly urgent prior-
ity (n = 74), or the screening was prematurely terminated 
because of clinical deterioration of the patient condition 
(n = 41). The remaining 808 patients were included for 
the present analysis (Fig. 2). The study cohort included 
524 men and 284 women with a median age 55 years 
(IQR, 47-62) at the time of colonoscopy (Table 1). 
The most frequent reason for pre–liver transplantation 
screening was alcoholic liver disease (22.9%), followed 
by viral hepatitis (21.4%) and primary sclerosing chol-
angitis (PSC) (17.6%) (Table 1). The prevalence of IBD 
in patients diagnosed with PSC was 59.9% (85/142 
patients). HCC was present in 223 patients (27.6%). 
The median MELD score was 15 (IQR, 11-18; range, 
6-40), 24.5% of patients had diuretic-responsive ascites, 
16.6% had refractory ascites, and 97 (12%) patients had 
HE at the time of colonoscopy. Approximately 20% of 
patients used at least one antibiotic agent during colo-
noscopy. One-fifth of patients received colorectal screen-
ing in the prior 5 years by colonoscopy; no cases were 
identified of patients undergoing colonoscopy after a 
positive screening with FOBT/FIT, CT colonography, 
or barium enema examination (Table 1).
ColoNoSCopy pRoCeDURe
A total of 864 colonoscopies were performed in 
808 patients. Bowel preparation adequacy was avail-
able in 663 patients and was scored as excellent in 
7.1%, good in 54.6%, fair in 16.1%, poor in 3.3%, 
and inadequate in 1%. Cecal intubation rate of the 
index colonoscopy was 96.7%. Cecal intubation failed 
because of loop formation in 15 patients and because 
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of abortion due to patient discomfort/abdominal pain 
in 12 patients. Multivariable logistic regression, car-
ried out for risk factors for cecal intubation failure, 
identified MELD score (odds ratio [OR], 1.090 per 
point; 95% confidence interval [CI], 1.015-1.170; 
P = 0.018) as an independent risk factor.
In total, 56 repeat colonoscopies were performed 
because of several reasons: poor bowel preparation (n 
= 13), initial cecal intubation failure (n = 25), antico-
agulation status contraindicated polypectomy (n = 9), 
patients needed a repeat colonoscopy after a period of 
3 years on the liver transplantation waiting list or for 
liver retransplantation (n = 6), or additional polypec-
tomy or surveillance after polypectomy (n = 3). In 6 
patients with initial cecal intubation failure and in 5 
patients with poor bowel preparation, subsequent colo-
noscopy was postponed until after the transplantation.
In this cohort, 799/864 (92.4%) colonoscopies were 
performed under conscious sedation using intravenous 
midazolam and fentanyl. Sixty-five procedures were 
performed using fentanyl (n = 25), remifentanil (n = 7), 
or without any premedication (n = 33). Patients did not 
receive standard periprocedural antibiotic prophylaxis.
DIagNoStIC yIelD
In total, 625 polypectomies were performed during 
colonoscopy, with an average of 2.3 polypectomies 
(±1.3) per patient. At colonoscopy, advanced neoplasia 
was found in 46 (5.6%) patients: advanced adenoma 
in 44 (5.4%) and CRC in 2 (0.2%). Nonadvanced 
adenoma was found in 151 patients (18.7%), includ-
ing SSA/P or TSA in 13 patients (1.6%), hyperplas-
tic polyps in 130 patients (16.1%), and inflammatory 
polyps in 3 patients (0.4%) (Table 2).
In 58 of the remaining 465 patients, a lesion was 
macroscopically present, but polypectomy was not 
attempted because of impaired coagulation and/or a 
macroscopically benign character (n = 41) or because 
histopathologic evaluation was not possible as a result 
of loss or insufficient yield of tissue (n = 17). At a sub-
sequent colonoscopy, advanced adenoma was diagnosed 
in 3 of 58 cases, and CRC was diagnosed in none.
The only independent risk factor for advanced neo-
plasia was age (odds ratio, 1.072 per year; 95% CI, 
1.031-1.115; P < 0.001). Advanced neoplasia was 
diagnosed in 5.6% of the patients aged 60 years or 
FIg. 2. Flow chart of study inclusion.
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older, in 5.4% of the patients aged 50-59 years, and 
in 1.8% of the patients aged 40-49 years; no advanced 
neoplasm was diagnosed below the age of 40 years 
(Fig. 3). The 2 patients with CRC were a 62-year-old 
female with a T2N0M0 rectal adenocarcinoma and a 
64-year-old female with a T2N0M0 adenocarcinoma 
of the sigmoid colon.
otHeR ColoN patHologIeS
In 294 patients (36.4%), other colon pathologies 
were reported (Table 2). There were no cases of newly 
diagnosed IBD.
CoMplICatIoNS aFteR 
ColoNoSCopy
During the 30-day period after colonoscopy, 178 
clinical events occurred in 128 (14.9%) patients com-
pared with 101 clinical events in 72 (8.6%) patients in 
the control time frames (P < 0.001) (Table 3).
After colonoscopy, there was a significantly increased 
risk for acute renal failure (33 vs. 10; P = 0.001). 
Patients with acute renal failure had an average creat-
inine rise of 66 μmol/L; 35 were treated with volume 
expansion, albumin, and/or vasopressors, and 8 were 
taBle 1. patient Baseline Clinical Characteristics at the 
time of Screening Colonoscopy
Patients (n = 808)
Male sex, n (%) 524 (64.9)
Age in years, median (IQR) 55 (47-62)
Cause of liver disease, n (%)
Alcoholic liver disease 185 (22.9)
Viral hepatitis 173 (21.4)
PSC 142 (17.6)
PBC/autoimmune hepatitis 65 (8.0)
Cryptogenic liver cirrhosis 58 (7.2)
NASH 41 (5.1)
Other 144 (17.8)
HCC, n (%) 223 (27.6)
Blood serum parameters
Creatinin (μmol/L), median (IQR) 71 (59-90)
Albumin (g/L), mean (SD) 33 (±7)
Bilirubin (μmol/L), mean (SD) 87 (±126)
INR, mean (SD) 1.4 (±0.4)
Liver disease severity scores
MELD score, median (IQR) 15 (11-18)
Child-Pugh class, n (%)
A 473 (58.5)
B 294 (36.4)
C 41 (5.1)
Ascites, n (%)
None 476 (58.9)
Diuretic-responsive 198 (24.5)
Refractory 134 (16.6)
HE, n (%)
None 711 (88.0)
West-Haven grade 1-2 71 (8.8)
West-Haven grade 3-4 26 (3.2)
Antibiotic use,* n (%) 162 (20.0)
Norfloxacin 82 (10.1)
Rifaximin 48 (5.9)
Rifamipicin 9 (1.1)
Ciprofloxacin 17 (2.1)
Amoxicilin and clavulanic acid 5 (0.6)
Other 12 (1.5)
Colorectal screening in the prior 5 
years, n (%)
193 (23.9)
*11 patients used multiple antibiotic agents.
Abbreviations: NASH, nonalcoholic steatohepatitis; PBC, primary 
biliary cirrhosis.
taBle 2. Findings at Colonoscopy
Patients (n = 808)
Diagnostic yield,* n (%)
CRC 2 (0.2)
Advanced adenoma 44 (5.4)
≥10 mm 17
≥25% villous 9
high-grade dysplasia 4
≥10 mm + high-grade dysplasia 3
≥10 mm + ≥25% villous 8
≥25% villous + high-grade 
dysplasia
1
≥10 mm + ≥25% villous + 
high-grade dysplasia
2
Nonadvanced adenoma 164 (20.3)
SSA/P or TSA 13
Hyperplastic polyp 130 (16.1)
Inflammatory polyp 3 (0.4)
No lesions 465 (57.6)
Other colon pathologies,† n (%)
IBD 92 (11.4)
Rectal varices 72 (8.9)
Angiodysplasia 61 (7.5)
Portal hypertension 58 (7.2)
Diverticulosis 57 (7.1)
Hemorrhoids 42 (5.2)
*According to the most advanced lesion.
†Patients could have multiple other pathologies.
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treated with dialysis. The presence of ascites (diuret-
ic-responsive ascites OR, 1.199; 95% CI, 0.356-4.038; 
refractory ascites OR, 5.384; 95% CI, 1.935-14.978; 
P = 0.001) and high MELD score (OR, 1.265 per 
point; 95% CI, 1.180-1.356; P < 0.001) were inde-
pendent risk factors for postcolonoscopy renal failure.
The risk for GI bleeding not originating from pol-
ypectomy sites was also significantly elevated after 
colonoscopy (25 vs. 11; P = 0.023). MELD score (OR, 
1.127 per point; 95% CI, 1.061-1.197; P < 0.001) was 
found to be an independent risk factor for postcolo-
noscopy GI bleeding.
FIg. 3. Most advanced lesion per participant found during colonoscopy.
taBle 3. Frequency of Complications in patients Undergoing Screening Colonoscopy
Complications During 30 Days After 
Colonoscopy (n = 858)
Complications During 30-Day Control 
Time Frame (n = 835) P Value
Acute renal failure, n (%) 33 (3.8) 10 (1.2) 0.001
Gastrointestinal bleed, n (%) 25 (2.9) 11 (1.3) 0.023
Bacterial infection, n (%) 54 (6.3) 37 (4.4) 0.089
SBP 18 17 —
Fever of unknown origin 15 6 —
Bloodstream infection 12 3 —
Respiratory infection 4 - —
GI infection 4 7 —
Urogenital infection 3 3 —
Other 0 1 —
HE, n (%) 47 (5.5) 32 (3.8) 0.109
Pulmonary complications, n (%) 10 (1.2) 3 (0.4) 0.058
(Aspiration) pneumonia 3 — —
Respiratory insufficiency 7 3 —
Cardiac complications, n (%) 7 (0.8) 4 (0.5) 0.391
New-onset arrhythmia 5 1 —
Congestive heart failure 2 2 —
Myocardial ischemia — 1 —
Ascites (new-onset or worsening), n (%) 1 (0.1) 4 (0.5) 0.169
Bilirubin increase, n (%) 1 (0.1) — 0.324
Note: Bold indicates a P value below 0.05.
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Furthermore, there was a nonsignificant increase 
in bacterial infections (54 vs. 37 cases; P = 0.089), 
HE (47 vs. 32 cases; P = 0.109), pulmonary com-
plications (10 vs. 3 cases; P = 0.058), and cardiac 
complications (7 vs. 4 cases; P = 0.391) in the post-
colonoscopy and control time frames, respectively 
(Table 3).
Postpolypectomy hemorrhage occurred in 2 patients; 
both could be endoscopically managed. In 1 patient, 
colon perforation occurred after polypectomy, which 
was successfully treated conservatively.
Because the study duration was 13.5 years, the 
impact of the time of screening was measured on the 
detection of advanced adenomas and complication 
occurrence. There were no statistically significant dif-
ferences regarding the time of screening on these out-
come measures (Supporting Fig. S1).
ClINICal CoURSe
The median follow-up time was 285 days (IQR, 
106-636). In this cohort, 260 patients (32.2%) died, 
432 patients (53.3%) received a liver transplant, and 
116 patients (14.4%) were waiting for a liver trans-
plant at the end of the observation period. The 1-year 
survival rate after liver transplantation was 91%, and 
the 2-year survival rate was 88%.
Discussion
In this study, we assessed the diagnostic yield 
and safety of performing a screening colonoscopy in 
patients evaluated for liver transplantation. We found 
that CRC was diagnosed in 0.2% of the population 
and that advanced adenoma was diagnosed in 5.4%. 
Age was the only significant predictive factor for 
advanced neoplasia. Furthermore, colonoscopy with 
standard PEG bowel preparation was associated with 
a significantly increased risk for renal failure and non-
polypectomy GI bleeding, especially in patients with 
the most severe liver disease.
A key finding of the present study is the relatively 
low prevalence of CRC in this patient population. 
These results are consistent with those of comparable 
studies that did not find any case of CRC in patients 
undergoing pretransplantation evaluation.(6,8,39) The 
5.4% prevalence of advanced adenomas in our study 
was comparable to that reported by Weismuller et al. 
(prevalence, 5.8%; 243 patients with a mean age of 
53 years) but differs markedly from the 13.9% preva-
lence (567 patients; median age of 54 years) reported 
by Jeschek et al.(6,8) These diverging results may be 
related to differences in study methodology, as the 
latter study results were not based on the actual diag-
nosed rate of advanced adenomas but were rather 
based on a statistical adjustment of this number, 
assuming the same rate of advanced adenomas among 
resected and nonresected polyps.(8) The results of 
large cohort studies assessing the prevalence rate of 
advanced neoplasms in unselected healthy subjects, 
although of slightly older age, are in line with those 
in our study. Imperiale et al. reported a CRC rate of 
0.6% and an advanced adenoma rate of 5.6% in 1,994 
patients with a mean age of 60 years, and Stoop et al. 
found a rate of 0.5% and 8.2%, respectively, in 1,276 
patients with a mean age of 61 years.(40,41)
Another important finding is that 53.5% of the 
population undergoing screening actually underwent 
liver transplantation. Although 14.4% are still wait-
ing for a liver transplant, a substantial proportion of 
patients have died on the waiting list or were not 
placed on the waiting list because of contraindications 
for liver transplantation.(42) Moreover, 9% of the 432 
patients who underwent transplantation died within 
1 year, and an additional 3% died in the second year 
after transplantation. Thus, the number of patients 
who could theoretically benefit from screening colo-
noscopy is further decreased by the operative and 
postoperative mortality.
Our results indicate that colonoscopy increases the 
risk for complications such as acute renal failure and 
GI bleeding. We hypothesize that this may be related 
to bowel preparation with an inherent substantial fluid 
load that may induce unwanted circulatory alterations 
and fluid shifts. Indeed, water retention in patients with 
a preexistent hyperdynamic circulation, increasing the 
portal venous pressure, has been reported in patients 
undergoing bowel preparation with decompensated 
liver disease, congestive heart failure, and chronic renal 
insufficiency.(13,43) Our study result that MELD score 
is the most important predictive factor for these com-
plications after colonoscopy supports this theory.
The cecal intubation rate of 96.7% in our study is 
fairly similar to the rate of 83%-96% found in other 
cohorts of patients evaluated for liver transplanta-
tion.(6,39) Multiple explanations are proposed for the 
slightly lower cecal intubation rate in this population 
Hepatology, June 2019OEY, VAN TILBURG ET AL.
2606
compared with that in healthy subjects. The presence 
of ascites may lead to more mobile bowel loops float-
ing in ascitic fluid and may lower the efficacy of exter-
nal abdominal pressure to reduce loop formation.(39) 
In addition, the cecal intubation rate may be adversely 
affected by other factors, including overall poor gen-
eral condition and reduced possibilities for effective 
use of premedication.(39) In the present study, MELD 
score was identified as an independent predictor for 
cecal intubation failure, which may support these 
hypotheses.
Currently, the American Association for the Study 
of the Liver clinical practice guideline recommends 
that liver transplantation candidates should undergo 
an age and risk factor–appropriate cancer screening, 
including colonoscopy without further specifica-
tions.(2) The European Association for the Study of 
the Liver clinical practice guideline states that CRC 
screening is mandatory for candidates older than 
50 years.(3) However, in light of the currently avail-
able data, the indication for standard pre–liver trans-
plantation screening colonoscopy may be questioned, 
considering the balance between yield and associated 
risks and costs and considering other important fac-
tors such as the substantial waiting list and perioper-
ative mortality.
We suggest that other screening strategies should 
be considered. A possible alternative approach could 
be the use of a FIT as a general first-line screening test 
in subjects aged 50 years or older and consideration of 
colonoscopy only in patients who have positive FIT 
results. Patients with IBD, primary sclerosing cholan-
gitis, or other conditions associated with an increased 
risk for CRC should be managed according to gener-
ally accepted guidelines.
This study systematically assessed the complica-
tion risk of pre–liver transplantation screening colo-
noscopy, taking into account the underlying general 
risk for unwanted events associated with liver disease. 
The considerable size of the study population and the 
completeness of data are other factors likely contrib-
uting to the reliability of our results. A limitation is 
that patients who underwent colonoscopy in another 
center before referral were not taken into account. 
However, this was a relatively small group, and our 
study design reflects the real-world situation in a 
referral hospital for liver transplantation. In addition, 
because of the retrospective design of the study, not 
all relevant factors, such as adequacy of bowel prepa-
ration, could be fully analyzed.
Future research projects regarding CRC screening 
in transplant candidates could focus on the assessment 
of factors relevant for more refined risk stratification 
in this population, such as age, sex, cause of liver dis-
ease, family history of CRC, body mass index, smok-
ing and drinking habits, and comorbidities such as 
diabetes. It may be equally important to prospectively 
assess the results of alternative screening strategies.
In conclusion, this study describes the yield and 
safety of colonoscopy in patients evaluated for liver 
transplantation screening and provides arguments 
for why a reconsideration of guidelines regarding the 
necessity of colonoscopy in unselected patients seems 
appropriate. We propose that alternative colorectal 
screening strategies should be considered and further 
explored.
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